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ABSTRACT Influenza vaccines targeting the highly conserved stem of the hemag-
glutinin (HA) surface glycoprotein have the potential to protect against pandemic
and drifted seasonal influenza viruses not covered by current vaccines. While HA
stem-based immunogens derived from group 1 influenza A viruses have been
shown to induce intragroup heterosubtypic protection, HA stem-specific antibody
lineages originating from group 2 may be more likely to possess broad cross-group
reactivity. We report the structure-guided development of mammalian-cell-expressed
candidate vaccine immunogens based on influenza A virus group 2 H3 and H7 HA
stem trimers displayed on self-assembling ferritin nanoparticles using an iterative,
multipronged approach involving helix stabilization, loop optimization, disulfide
bond addition, and side-chain repacking. These immunogens were thermostable,
formed uniform and symmetric nanoparticles, were recognized by cross-group-
reactive broadly neutralizing antibodies (bNAbs) with nanomolar affinity, and elicited
protective, homosubtypic antibodies in mice. Importantly, several immunogens were
able to activate B cells expressing inferred unmutated common ancestor (UCA) ver-
sions of cross-group-reactive human bNAbs from two multidonor classes, suggesting
they could initiate elicitation of these bNAbs in humans.
IMPORTANCE Current influenza vaccines are primarily strain specific, requiring an-
nual updates, and offer minimal protection against drifted seasonal or pandemic
strains. The highly conserved stem region of hemagglutinin (HA) of group 2 influ-
enza A virus subtypes is a promising target for vaccine elicitation of broad cross-
group protection against divergent strains. We used structure-guided protein engi-
neering employing multiple protein stabilization methods simultaneously to develop
group 2 HA stem-based candidate influenza A virus immunogens displayed as trim-
ers on self-assembling nanoparticles. Characterization of antigenicity, thermostability,
and particle formation confirmed structural integrity. Group 2 HA stem antigen de-
signs were identified that, when displayed on ferritin nanoparticles, activated B cells
expressing inferred unmutated common ancestor (UCA) versions of human antibody
lineages associated with cross-group-reactive, broadly neutralizing antibodies
(bNAbs). Immunization of mice led to protection against a lethal homosubtypic in-
fluenza virus challenge. These candidate vaccines are now being manufactured for
clinical evaluation.
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Influenza continues to be a significant global health burden, typically resulting inabout 500,000 deaths worldwide annually (1), even though the technology for
conventional egg-grown, whole inactivated influenza virus vaccines was developed
more than 70 years ago. Constant antigenic drift of the influenza virus hemagglutinin
(HA) coupled with immunodominant strain-specific antibody responses directed to the
variable HA head domain results in conventional vaccine effectiveness ranging from 10
to 60% (2) and the need for seasonal updates of virus strains included in licensed
vaccines. Furthermore, current vaccine approaches provide minimal protection against
pandemic influenza virus strains (3, 4). Improved influenza vaccines would not be
produced in eggs, would be designed to induce broad immunity against future drifted
and pandemic strains without seasonal reformulation, and would elicit durable immune
responses, avoiding the need for annual vaccination (4). One approach for achieving
broadly cross-reactive influenza virus-specific antibodies is to target highly conserved
neutralization-sensitive epitopes in the stem region of the influenza A virus HA surface
glycoprotein (5). Monoclonal antibodies (MAb) have been identified that bind con-
served HA stem epitopes and possess broad neutralizing activity across diverse HA
subtypes within an influenza A virus group, as well as some that have cross-group
neutralizing activity (6–16). We and others have recently developed influenza A virus
group 1 HA stem trimer antigens (17, 18). One candidate displaying H1-based HA stem
trimers on self-assembling ferritin nanoparticles protected mice and ferrets from a
lethal heterosubtypic H5N1 influenza challenge (17). However, these group 1 HA stem
immunogens did not provide cross-group protection against group 2 viruses, such as
H3N2 and H7N9. The need for a better group 2 vaccine is particularly acute, as vaccine
effectiveness against H3N2 over the past decade has averaged only 33% (19), recent
H3N2 strains have exhibited increased virulence (20), and H7 viruses represent one of
the greatest pandemic threats from nonseasonal strains. H7N9 immunization was
recently shown to induce multiple HA stem-directed antibody lineages in humans that
recognized both group 1 and group 2 HA molecules, whereas H5N1 immunization
induced primarily HV1-69 antibody lineages that cross-reacted primarily within group
1 influenza A virus subtypes (13). This suggests that group 2 HA stem immunogens may
be more effective at inducing cross-group responses than group 1 immunogens in
humans with preexisting influenza immunity or at priming multidonor antibody lin-
eages with the capacity for broad neutralizing activity in influenza-naive infants. In our
studies, we used iterative structure-based design to develop headless group 2 HA
stabilized stem trimers displayed on ferritin nanoparticles based on hemagglutinin
sequences from H3N2 (H3ssF) and H7N9 (H7ssF) viruses as candidate vaccines. Notably,
structural subtleties ultimately required the use of a set of design strategies to stabilize
group 2 HA stem immunogens that was completely different than the simpler hydro-
phobic repacking used to stabilize group 1 immunogens. Ultimately, H3ssF and H7ssF
immunogen designs were identified that could activate B cells expressing inferred
unmutated common ancestor (UCA) of HA stem-directed human broadly neutralizing
antibodies (bNAbs), suggesting the potential for inducing cross-reactive antibody
lineages with the capacity to develop broad influenza virus neutralizing activity in
humans.
RESULTS
Design of group 2 stabilized HA stem nanoparticle immunogens. The initial
design of group 2 stabilized HA stem nanoparticles incorporated some features of
group 1 H1-stabilized HA stem nanoparticle immunogens (17) (referred to as H1ssF
herein). This comprised replacing the HA head region (HA1 residues 43 to 313, H3
numbering [21]) with a GSG loop, replacing the HA2 interhelical region (residues 60 to
92) with a 6-residue glycine-rich loop, including two repacking substitutions in the HA2
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hydrophobic core (replacing K with M at position 103 [K103M] and E with L at position
51 [E51L]), and connecting the C-terminal HA2 residue 174 to the N-terminal residue 5
of bacterial ferritin with a short SGG linker (Fig. 1A; Fig. S1 and S2 in the supplemental
material). In the group 1 context, this strategy was sufficient for displaying antigenically
correct H1, H2, and H5 HA stem trimers on ferritin nanoparticles (17). However, multiple
FIG 1 Structure-based design of group 2 HA stem nanoparticles. (A) Ribbon models depicting the HA stem nanoparticle design pathway for stabilizing the
HA stem starting from an H3N2 HA trimer ectodomain. Two of the three protomers are gray, and one protomer is cyan with the design modifications in red.
Positive or negative outcomes are indicated by green or black arrows, respectively, below each step. bNAb, broadly neutralizing antibody. (B) Maximum-
likelihood phylogenetic trees for protein sequences from representative full-length HAs (top) and HA stems (bottom) of the 18 different subtypes. Group 1
subtypes are dark blue, and group 2 subtypes are cyan. (C) A molecular model of the HA stem of an H3ssF_C design is shown colored as described for panel
A. Two of the three protomers are depicted as surface representations, and one protomer is displayed as a ribbon diagram. Insets show close-ups of the
modified regions with stick representations for side chains of modified residues. Surface representations are removed from some insets for clarity. PDB entry
2YP2 was used as an H3N2 model template.
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additional steps were needed to achieve the expression of group 2 H3 and H7 HA stem
nanoparticles in mammalian HEK293 cells (Fig. 1). Although there is structural similarity
between H1 and H3 HA stem regions (e.g., root mean square deviation [RMSD] of 1.0 Å
for 134 stem residues between A/California/04/2009 [H1N1; PDB identification code [ID]
3UBQ] and A/Victoria/361/2011 [H3N2; PDB ID 4O5N]) and sequence identity of ap-
proximately 55%, phylogenetic analysis indicates groups 1 and 2 comprise two distinct
branches with consistent and predictable amino acid differences even for the stem
region of HA (Fig. 1B). We hypothesized that further structural stabilization was
required for expression, and therefore, an iterative structure-based design effort was
employed to stabilize the HA stem region of H3ssF immunogens, using the 1.9-Å-
resolution crystal structure of HA for A/Finland/486/2004 (H3N2; PDB ID 2YP2) (22) as
a template. To screen for expression and correct antigenicity, designs were expressed
in HEK293T cells using a high-throughput 96-well format (23). Supernatants containing
HA stem trimers genetically fused to ferritin nanoparticles were assessed directly for
antigenic recognition either by an immunoprecipitation assay using the human cross-
group HA stem-specific bNAb FI6v3 or by an enzyme-linked immunosorbent assay
(ELISA) using the bNAbs CR9114, FI6v3, and CT149. CT149 was specifically included to
assess trimer integrity because its epitope incorporates two adjacent protomers of the
HA stem and, thus, may be sensitive to quaternary structure (15).
Since internal hydrophobic repacking mutations were critical for the stabilization of
the group 1 HA stem immunogens (17) and the burying of just a single -CH2- group in
a protein interior can add approximately 1.1 kcal/mol of free energy to protein stability
(24, 25), we explored additional repacking mutations selected computationally using
Rosetta (26). In combination with some of the repacking mutations, we also explored
limited residue swapping between H1N1 and H3N2 subtypes (Table S1). Surprisingly,
none of these 174 mutants could be expressed and recognized by the bNAb CR9114 or
FI6v3 (Table S1), indicating that novel approaches for structural stabilization would be
required.
Upon further investigation of multiple protein stabilization strategies involving
another 76 designs (Table S1), a lead design was successfully expressed (H3ssF_A) that
was recognized by bNAb HA stem antibody FI6v3 by immunoprecipitation and self-
assembled into nanoparticles (Table 1; Table S1, Fig. S2 and S3). H3ssF_A included the
initial H1ssF-based mutations in addition to (i) helix stabilization, (ii) loop optimization,
and (iii) point mutations of select H3 residues to improve internal packing (Fig. 1A and
C; Fig. S2A). Each of the successful alterations was focused on the membrane distal end
of the two central helices (A and C) of the HA2 fold. The outer helix A in H3N2 HA is
approximately 5 residues shorter at its C terminus than in H1 HA, and it is known that
helix length is related to stability (27). Therefore, helix A was extended at its C terminus
by 5 residues (ALMAQ) with high helix-forming propensities (28). Likewise, the N
terminus of the adjacent helix C was stabilized by adding an N-terminal Asp (HA2 92)
as a helix-capping residue (29, 30), and two other mutations (HA2 S93A and N95L) were
made at the N terminus of helix C to increase its helix-forming propensity and improve
interprotomer packing (Fig. 1C). Biophysical studies have shown that excess loop length
can destabilize protein folds by up to several kcal/mol (31), and in the initial H1ssF and
H3ssF designs, helices A and C were connected by a 6-residue linker even though they
are separated by only 12 Å. Therefore, the glycine-rich linker was shortened to a
4-residue GGPD linker to more closely match the interhelical distance. Finally, 4 residues
(HA2 52, 55, 107, and 116) on helices A and C were mutated to improve side-chain
packing (Fig. 1C; Fig. S2A). Three of these (HA2 52, 55, and 116) comprised mutations
to H1 residues.
To further improve expression and stability, another 45 designs were explored,
focusing on the short -hairpin connected to a 3-residue loop which replaced the HA
head in HA1 (Fig. 1). Since the stability of short, two-stranded -sheets has been
observed to increase with length (32), we replaced the GSG loop with longer loops of
6 or 7 residues designed to double the hairpin length. Residues with high strand-
forming propensities (28), such as Val, Ile, and Phe, were used for strand extension, and
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dipeptides with propensities to form -turns (33, 34), such as PG and NG, were used to
connect them. Disulfides were also designed into the hairpin loops for added stability
(35). From an initial survey of loop extensions, H3ssF_B, designed with a 7-residue
hairpin loop extension disulfide bonded to the N terminus of helix C, resulted in
expression levels of more than 5 mg/liter and recognition by CT149 (Fig. 1, Table 1;
Table S1).
Further loop optimization of the H3ssF_B design included removing a glycine from
either side of the cysteine in the -hairpin loop (H3ssF_D and H3ssF_E) and incorpo-
rating a different -hairpin sequence with an internal disulfide bond engineered to link
both strands together (H3ssF_G). Additional H3ssF_B variants incorporated hydrophilic,
helix-preferring Glu into the relatively hydrophobic helix A extension motif, for im-
proved solubility (H3ssF_C, H3ssF_F, and H3ssF_H), and an engineered intraprotomer
disulfide between HA1 residues 23 and 322 (H3ssF_H). All six variants resulted in
nanoparticles recognized by CT149 in ELISAs but did not improve overall expression
beyond that of H3ssF_B. Based on the successful expression and antigenic recognition
of multiple H3ssF variants, we transferred mutations from constructs H3ssF_B, H3ssF_C,
H3ssF_D, H3ssF_E, and H3ssF_F into analogous H7ssF nanoparticles using sequences
from the human H7N9 strain (A/Shanghai/2/2013) and also created two additional loop
variants (H7ssF_I and H7ssF_J) (Table 1; Fig. S2B). All seven of these H7ssF designs
expressed milligram-per-liter quantities of nanoparticles recognized by CT149 (Ta-
ble S1).
Physical characterization of H3ssF and H7ssF nanoparticles. Fourteen nanopar-
ticles were selected for further characterization. These were purified by lectin chroma-
tography followed by size exclusion chromatography, which resulted in distinct peaks
consistent with approximately 1.2-MDa particles (Fig. 2A and B; Fig. S4). Negative-stain
electron microscopy of purified nanoparticles followed by reference-free 2-dimensional
(2-D) classification and averaging revealed spherical particles with five or six visible,
regularly spaced, protruding spikes (Fig. 2C to F; Fig. S4). All nanoparticles contained
ferritin cores consistent with the expected 12- to 13-nm diameter and HA stems with
the expected length of approximately 7 nm (Table 1).
Thermostability of H3ssF and H7ssF nanoparticles. We next investigated im-
munogen thermostability using differential scanning calorimetry (DSC). DSC measure-




















H3 H3ssF_A --GSG-- ALMAQ GGP DAYL NA  NDh ND ND
H3 H3ssF_B VFPGCGV ALMAQ GGP DCYL DS1  66.2 124.0  7.0 82.0  9.0
H7 H7ssF_B  58.6 126.9  6.8 71.6  6.5
H3 H3ssF_C VFPGCGV ELMEQ GGP DCYL DS1  66.6 123.2  3.4 65.0  5.2
H7 H7ssF_C  61.6 124.4  4.4 66.9  6.4
H3 H3ssF_D VFPGC-V ALMAQ GGP DCYL DS1  66.3 125.3  5.1 67.7  12.4
H7 H7ssF_D  61.2 139.7  4.8 64.8  3.4
H3 H3ssF_E VFP-CGV ALMAQ GGP DCYL DS1  63.0 130.1  5.3 66.9  7.2
H7 H7ssF_E  56.7 124.7  6.5 68.1  2.7
H3 H3ssF_F VFPGCGV ALMEE GGP DCYL DS1  65.6 127.1  6.0 67.0  4.1
H7 H7ssF_F  59.9 130.2  6.3 65.1  5.5
H3 H3ssF_G CFNGIC- ALMAQ GGP DAYL DS2  59.9 126.3  4.0 68.5  3.3
H3 H3ssF_H VFPGCGV ELMEQ GGP DCYL DS1, DS3  56.6 126.9  3.5 67.8  4.5
H7 H7ssF_I VFPNCGV ALMAQ GGP DCYL DS1  58.7 124.3  4.1 68.4  6.6
H7 H7ssF_J VFPGCGV ALMAQ GPP DCYL DS1  57.0 131.4  5.1 62.6  7.6
aBetween HA1 residues 42 and 314 (H3 numbering).
bDirectly following HA1 56.
cDirectly following the helix A extension.
dRegion between the interhelix loop and HA2 96.
eDS1, HA1 C145-HA2 C93; DS2, HA1 C141-C146; DS3, HA1 C23-C322; NA, not applicable.
fBased on gel electrophoresis analysis of unpurified supernatants following transient transfection.
gEM, electron microscopy.
hND, not determined.
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ments revealed thermal melting temperatures (Tm) for the earliest transitions ranging
from 56.6 to 66.6°C for H3ssF variants and 56.7 to 61.6°C for H7ssF variants (Table 1;
Fig. S5A and B). Three other, higher temperature transitions at approximately 78, 96,
and 106°C were consistently observed for all the immunogens tested. In contrast, the
ferritin nanoparticle alone had a primary transition at 105.7°C and a minor one at 84°C.
Since the earliest transitions were the most variable, we hypothesized that these were
related to the HA stem structures.
The three H3ssF designs with the highest Tms, ranging from 66.2 to 66.6°C, had
either the 7-residue -hairpin extension disulfide bonded to helix C (H3ssF_B and
H3ssF_C) or the same loop with one glycine removed just after the cysteine (H3ssF_D).
Glycine removal just prior to the cysteine (H3ssF_E) was less well tolerated thermody-
namically. Curiously, H3ssF_H with the same hairpin loop as H3ssF_B and H3ssF_C but
designed to contain an additional disulfide bond to stabilize the HA1 region of the stem
had the lowest Tm, 56.6°C, indicating that this variant had less than optimal stability.
Design H3ssF_G, engineered to have an internal disulfide bond in the -hairpin
extension, had a Tm 6°C lower than those of H3ssF_B and H3ssF_C. Incorporation of Glu
into the two Ala positions in the 5-residue helix A extension had little effect on stability
(H3ssF_C), but Glu incorporation to replace the last two residues decreased the Tm by
1°C (H3ssF_F). For the five immunogen designs (B to F) made in both H3 and H7
formats, the Tm values were on average 5.9°C higher for the H3ssF than for the H7ssF
designs, and similar trends were observed between designs. Finally, two additional
H7ssF variants not represented in H3ssF, with an Asn incorporated into the HA1
-hairpin extension (H7ssF_H) and a Pro incorporated into the HA2 GGP loop (H7ssF_I),
did not significantly alter the Tm. While improved thermostability will facilitate vaccine
transport and storage, increasing rigidity and stability of antigens can sometimes be
counterproductive for immunogenicity (36). Therefore, multiple designs with various
levels of DSC-determined stability were advanced for further evaluation.
Antigenicity of H3ssF and H7ssF nanoparticles. Biolayer interferometry (BLI) was
used to measure the binding kinetics and affinities of nanoparticles for antigen-binding
FIG 2 Physical characterization of group 2 HA stem nanoparticles. Gel filtration chromatograms for lectin-purified H3ssF
(A) and H7ssF (B) nanoparticles reveal single peaks. (C to F) Negative-stain electron microscopy 2-D class averages for H3ssF
(C, D) and H7ssF (E, F) B and C variants demonstrate the formation of particles with visible arrangements of HA stem trimers
projecting from hollow spheres. White bars represent 10-nm size markers.
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fragments (Fabs) of bNAbs MEDI8852, CT149, and CR8020 (Table 2; Fig. S6 and S7). To
avoid avidity effects, the nanoparticles were immobilized to anti-Fc-decorated sensors
using the bNAb CR9114 IgG and monovalent Fabs were used as the analyte. CR9114
Fab was observed to recognize H3ssF and H7ssF immunogens with affinities of 94 and
48 nM, respectively (Table 2; Fig. S6E). However, given the bivalent nature of the
CR9114 IgG and the 24 epitope sites on each nanoparticle, the avidity of this complex
was more than enough to stably immobilize nanoparticles to the sensor for measure-
ments of high-affinity bNAb Fabs.
The first two antibodies (MEDI8852 and CT149) recognize similar HA stem epitopes
centered on the HA2 helix A and fusion peptide loop supersite and represent two
multidonor classes of cross-group bNAbs (HV6-1HD3-3 class and HV1-18 QXXV class,
respectively) recently identified in healthy human adults vaccinated with H5N1 (12, 14,
15). CR8020 is a group 2-specific bNAb that recognizes a less conserved, more
membrane-proximal HA stem epitope (11). The HV6-1HD3-3 class MAb MEDI8852
recognized all H3ssF and H7ssF nanoparticles, as well as full-length H3 and H7 HA
trimers, with similar nanomolar affinities and kinetics (Table 2; Fig. S6A and B). The
HV1-18 QXXV class MAb CT149 also recognized all H7ssF nanoparticles with approxi-
mately 1 to 10 nanomolar affinity. Of these, H7ssF_C was recognized with approxi-
mately 10-fold-greater affinity (0.9 nM) and a 10-fold-slower off rate (5.3  104 s1)
than the other H7ssF nanoparticles. However, among the H3ssF nanoparticles, only
H3ssF_C and H3ssF_H were recognized by CT149, with affinities of 21.3 to 22.2 nM; the
other four H3ssF immunogens showed no measurable affinity to CT149 (Table 2;
Fig. S6). This was surprising, since each of these designs was initially chosen based on
strong binding to CT149 in ELISAs. Furthermore, ELISAs performed on purified H3 and
H7 immunogens for designs B and C also indicated a high affinity to each of the group
2-reactive HA stem antibodies tested (Fig. S7A). This apparent disparity between BLI
and ELISA was potentially due to utilization of bivalent IgGs in ELISAs as opposed to
monovalent Fabs in BLI assays, which provides an avidity advantage for apparent
binding affinity of up to 2 orders of magnitude (37–39). Consistent with this idea, we
observed in ELISAs that the Fab form of CT149 did not bind to H3ssF_B or H3ssF_C and
bound only modestly to H7ssF_B and H7ssF_C (Fig. S7B). Moreover, ELISAs used higher
densities of immobilized antigen than BLI, and there are inherent differences in the
methodologies of the two assays. Full-length H3 and H7 HA trimers were observed to
bind CT149 with affinities and kinetics consistent with those of the C and H versions of
the H3ssF and H7ssF nanoparticles (Fig. S6C to D). Interestingly, the nanoparticles with
TABLE 2 Antigenicity of the H3ssF and H7ssF nanoparticles for Fab forms of bNAbs as determined by BLIa
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H3ssF_A ND ND ND ND ND ND ND ND ND ND ND ND
H3ssF_B NB NB NB 0.7 2.9  105 2.2  104 20.9 2.8  105 5.8  103 ND ND ND
H7ssF_B 7.0 4.2  105 3.0  103 1.0 2.6  105 2.6  104 NB NB NB ND ND ND
H3ssF_C 21.3 8.1  105 1.7  102 0.8 3.0  105 2.4  104 23.3 2.4  105 5.5  103 93.6 7.0  104 6.5  103
H7ssF_C 0.9 6.0  105 5.3  104 1.0 2.7  105 2.6  104 NB NB NB 47.9 1.0  105 4.8  103
H3ssF_D NB NB NB 1.1 2.9  105 3.2  104 21.7 2.8  105 6.0  103 ND ND ND
H7ssF_D 9.0 3.7  105 3.3  103 0.9 2.7  105 2.3  104 NB NB NB ND ND ND
H3ssF_E NB NB NB 1.2 3.2  105 3.7  104 18.7 3.0  105 5.7  103 ND ND ND
H7ssF_E 8.2 3.7  105 3.0  103 0.8 2.9  105 2.4  104 NB NB NB ND ND ND
H3ssF_F ND ND ND ND ND ND ND ND ND ND ND ND
H7ssF_F 2.7 6.7  105 1.8  103 0.9 2.9  105 2.4  104 NB NB NB ND ND ND
H3ssF_G NB NB NB 0.9 3.0  105 2.6  104 17.9 2.7  105 4.8  103 ND ND ND
H3ssF_H 22.2 8.2  105 1.8  102 ND ND ND ND ND ND ND ND ND
H7ssF_I 7.2 4.1  105 2.9  103 1.0 2.6  105 2.7  104 NB NB NB ND ND ND
H7ssF_J 9.8 3.5  105 3.4  103 1.9 2.5  105 4.9  104 NB NB NB ND ND ND
H3 HA 42.2 7.5  104 3.2  103 1.2 1.3  105 1.5  104 ND ND ND ND ND ND
H7 HA 3.7 3.6  105 3.1  103 1.2 1.1  105 1.3  104 ND ND ND ND ND ND
aKD, equilibrium dissociation constant; Kon, association rate constant; Koff, dissociation rate constant; ND, not determined; NB, no detectable binding.
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greatest affinity for CT149, H3ssF_C, H3ssF_H, and H7ssF_C were each designed to have
two outwardly facing Glu residues at the C-terminal end of helix A, whereas the other
designs had Ala at these positions.
The group 2-specific HA stem bNAb CR8020 recognized all of the H3ssF nanopar-
ticles tested with affinities of 17.9 to 23.3 nM but did not recognize any of the H7ssF
nanoparticles (Table 2; Fig. S7C). This is consistent with the previously reported lack of
CR8020 binding to full-length A/Shanghai/2/2013 (H7N9) HA, the same strain used in
the H7ssF designs (40). The CR8020 epitope is not completely conserved even among
group 2 HAs, as there are six epitope mutations between the A/Hong Kong/1/1968
(H3N2) HA and the A/Shanghai/2/2013 (H7N9) HA.
Newly recombined, naive B cell receptors (BCRs) need to first recognize an immuno-
gen to initiate affinity maturation and B cell proliferation (41). Therefore, we also used
BLI to assess the relative affinities of three sets of mature stem bNAbs and their inferred
UCAs to HA stem nanoparticle immunogens (Fig. S7D). The UCAs were each inferred
phylogenetically from multiple clonal family members and include unmutated CDRH3
loops (Fig. S8). Two of these (54-1G07 and 09-1B12) were from the human multidonor
HV6-1HD3-3 class and HV1-18 QXXV class, respectively (13). The third antibody,
04-1D02, was from an HV3-53HD3-3 lineage. Measurable H3ssF and H7ssF immuno-
gen recognition by inferred UCAs for each of the three antibodies was not considerably
different from the binding of mature forms of the antibodies or the CR9114 positive
control (Fig. S7D). This is interesting, considering that there are 2 to 5 unmutated
CDRH3 residues in these UCAs (Fig. S8) and crystal structures of MAb complexes with
HA show considerable CDRH3 binding for members of the HV1-18 QXXV and HV6-1
HD3-3 multidonor antibody classes (12, 14, 15).
Immunogenicity of H3ssF and H7ssF nanoparticles. To evaluate the immunoge-
nicity of the group 2 HA stem nanoparticles, we immunized mice three times intra-
muscularly at 4-week intervals with the B and C designs of H3ssF and H7ssF. Both H3ssF
and H7ssF elicited robust homosubtypic antibody responses against H3 and H7,
respectively (Fig. 3A and B). Similarly, strong homotypic H3ssF and H7ssF neutralizing
antibody responses were elicited against H3N2 A/Wisconsin/67/2005 and H7N9 A/An-
hui/1/2013 pseudoviruses, respectively (Fig. 3C and D). For both H3 and H7, B and C
designs elicited similar levels of antibody responses (Fig. 3A to D). Following homo-
subtypic challenges, H3ssF-vaccinated mice were fully protected against H3N2 A/Phil-
ippines/2/1982 influenza virus (Fig. 3E, H3ssF_C); likewise, H7ssF vaccination fully
protected mice from H7N9 A/Anhui/1/2013 (Fig. 3G, H7ssF_C). Overall, these animal
studies demonstrated robust immunogenicity and protective efficacy of our group 2
HA stem nanoparticles against homotypic viruses, with limited cross-recognition of
heterosubtypic strains by elicited sera. Although the stabilized group 2 HA stem
antigens are immunogenic and protective, the murine species tested does not have the
appropriate B cell repertoire to evaluate the potential for eliciting bNAbs with specific
characteristics similar to those of known classes of human MAbs with cross-subtype
binding (12, 42, 43).
B cell activation by H3ssF and H7ssF nanoparticles. Recent studies have indi-
cated that characterization of in vitro engagement of V gene-reverted BCRs by antigen
can be used to assess and assign rank order to vaccine immunogens (43). Therefore, to
better understand how the immunogens may be able to engage elements of the
human antibody repertoire, Ca flux assays were used to measure activation of
Ramos B cells expressing IgM versions of the inferred UCAs of the human antibodies
16.a.26 and 54-1G07, representing two multidonor classes of cross-group human
bNAbs (HV1-18 QXXV class and HV6-1HD3-3 class, respectively) (12, 13, 43). All eight
H3ssF and H7ssF designs tested strongly activated the 54-1G07 UCA BCRs, with
magnitudes comparable to that of the anti-IgM control, whereas a group 1 H1ssF
negative control resulted in no activation (Fig. 4, left column). In contrast, only two
H3ssF immunogens (H3ssF_C and H3ssF_H) and one H7ssF immunogen (H7ssF_C) were
observed to elicit a strong activation of the 16.a.26 UCA BCR (Fig. 4, middle column). No
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activation of the HV4-34 group 1-specific 01.a.44 UCA BCR was observed (Fig. 4, right
column) (12). Notably, these results were consistent with the BLI binding data. In both
sets of experiments, the representatives of the multidonor HV6-1HD3-3 class bNAbs
engaged all of the H3ssF and H7ssF immunogens tested and the representatives of the
multidonor HV1-18 QXXV class bNAbs engaged only the C and H design immunogens
that contain added Glu in the helix A C-terminal extension. Our results suggest that
FIG 3 Immunogenicity of group 2 HA stem nanoparticles in mice. BALB/c mice were immunized with H3ssF or H7ssF. B
and C design groups were tested in separate experiments. (A to D) Serum was assessed for binding antibodies to H3
A/Hong Kong/1/1968 HA (A) and H7 A/Anhui/1/2013 HA (B) and neutralizing antibodies against H3N2 A/Wisconsin/67/
2005 (C) or H7N9 A/Anhui/1/2013 (D) pseudovirus. (E to H) H3ssF_C- and H7ssF_C-immunized mice were challenged with
lethal doses of H3N2 A/Philippines/2/1982 or H7N9 A/Anhui/1/2013, respectively. Survival (E, G) and weight loss (F, H) were
recorded postchallenge. Dotted lines in panels A to D represent assay limits of detection. One-way ANOVA with
Kruskal-Wallis posttest was used to compare mean ELISA and IC50 titers between groups. *, P  0.05; **, P  0.01; ***,
P  0.001; ****, P  0.0001.
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these C and H designs could potentially activate nascent B cells expressing unmutated
versions of multidonor HV6-1HD3-3 or HV1-18 QXXV class bNAbs to initiate B cell
proliferation and affinity maturation, thereby eliciting cross-group-reactive bNAb re-
sponses.
DISCUSSION
To address the need for influenza virus immunogens that can elicit broad hetero-
subtypic responses in humans, particularly against group 2 influenza A virus, we used
an iterative, structure-based design to develop headless group 2 HA stem-only nano-
particle immunogens from both H3 and H7 influenza virus subtype sequences. Stabi-
lizing the group 2 HA stem was unexpectedly difficult compared to doing so for group
1 HA stem antigens. In addition to modifications used to achieve antigenically correct
and immunogenic H1ssF candidate vaccines (17), multiple combined protein engineer-
ing strategies, including helix stabilization, loop optimization, and side-chain repacking,
were required to achieve the first lead design candidate. Without all three stabilization
strategies, the HA stem trimers were not stable enough to be expressed and displayed
on self-assembling ferritin nanoparticles. This suggests that screening multiple stabili-
FIG 4 Group 2 HA stem immunogens activate B cells expressing the inferred UCA versions of multidonor cross-group-reactive human BCRs. The
results from Ca flux assays indicate B cell activation by the IgM positive control and a group 1 H1ssF (A), H3ssF variants (B), and H7ssF variants
(C). BCR activation is displayed for the group 2-specific 54-1G07 UCA, group 2-specific 16.a.26 UCA activation, and group 1-specific 01.a.44 control
BCRs. Ca flux was measured by flow cytometry as the ratio (y axis) of the Ca-bound/-unbound states of the Ca-sensitive dye fura red over
time in seconds (x axis). Each experiment was repeated three times, and representative curves from one of the repeats are shown for each cell
line.
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zation methods concurrently may be necessary to design vaccine antigens from
metastable proteins or proteins that have had significant portions removed.
Ultimately, H3ssF and H7ssF immunogen designs were identified that provided
uniform, thermostable nanoparticles recognized by HA stem-directed bNAbs with
subnanomolar to nanomolar affinity. Additionally, H3ssF and H7ssF were immunogenic
in mice, eliciting robust homotypic neutralizing antibody responses that fully protected
mice against homosubtypic lethal challenges.
The unique antibody repertoire of humans makes it difficult to predict or model the
human immune response of candidate influenza vaccines using currently available
animal models like mice (42, 44) or ferrets, particularly given the specific classes of
human V, D, or J gene combinations associated with broadly cross-reactive immune
responses across multiple individuals (12). Therefore, instead of relying on a mouse
model to assess the potential breadth of antibody response, we utilized in vitro Ca
flux assays (43) to evaluate the ability of group 2 HA stem immunogens to activate B
cells expressing IgM BCRs comprising inferred UCA forms of the human, cross-group-
reactive, HA stem-directed bNAbs from two multidonor classes (12). Germline targeting
with vaccines designed to initiate specific antibody lineages is a new concept being
tested with HIV antigens and not yet proven as a way of achieving broad immunity in
humans. Even when transgenic animals are used for preclinical evaluation, the artificial
constraints imposed may lessen correlations with the human immune system. Further-
more, since this type of strategy is intended to enhance de novo antibody responses,
it may be particularly difficult to evaluate in preimmune adults and may require clinical
evaluation in naive children to demonstrate proof of concept.
Consistency with the BLI binding results informed the choice to focus on immuno-
gens H3ssF_C, H3ssF_H, and H7ssF_C, each of which was designed to have two
outwardly facing surface Glu’s (at positions i and i  3) at the C terminus of helix A. The
first Glu occurs at a position (HA2 57) that naturally has a Glu in most human H3 strains
from before 2002 and the majority of human H7 and H10 strains, although it is not in
a helical conformation in full-length HA. Modeling with CT149 suggests the two Glu
residues might interact with light-chain CDRL1 and CDRL2 loops (Fig. S9).
The observation that H3ssF and H7ssF variants were able to activate inferred UCA
versions of cross-reactive BCRs suggests that these immunogens could potentially
induce broad cross-group multidonor antibodies in humans. Due to their broad het-
erosubtypic breadth (12, 14, 15), such antibodies could potentially protect against
pandemic strains, in addition to drifted seasonal strains, and preclude the need for
annual vaccine reformulations. Furthermore, group 2 HA immunogens based on con-
ventional H7N9 monovalent split product formulations have been shown to induce
more diverse lineages of cross-group-reactive HA stem antibodies than conventional
group 1 H5N1 immunogens in humans (13). Immunological imprinting from earlier or
first exposures has also been suggested to play a significant role in shaping the
subsequent immune response to influenza virus (45, 46). Thus, in influenza virus-naive
individuals, the order of antigen priming may influence the composition of the influ-
enza virus-specific B cell repertoire. Current vaccine approaches combine multiple
strains of influenza virus in a single formulation. While this may be an effective strategy
in adults with preexisting immunity from prior infections and vaccinations, it is possible
that using an influenza A virus group 2 HA stem-based vaccine as the primary antigen
exposure in children could potentially imprint or prime for broader cross-group re-
sponses later in life. Moreover, since titers of anti-HA stem antibodies increase with age
and are inversely correlated with influenza virus infection rates, any early robust
induction of broad, cross-reactive HA stem antibodies has the potential to mitigate the
relatively high incidence of severe influenza disease in children, in addition to aug-
menting protection from influenza later in life (47). For adults and the elderly who have
likely already encountered influenza virus, the group 2 stem immunogens could
selectively boost antibody responses with greater breadth by not engaging otherwise
predominant group 1 HA stem-specific HV1-69 antibodies (48, 49). These group 2
immunogens complement our earlier development of group 1 HA stem immunogens,
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which were demonstrated to elicit within-group heterosubtypic protection in mice and
ferrets (17). Group 1 HA stem immunogens could potentially be used as a boost for the
group 2 HA stem immunogens to better focus the antibody response to the
neutralization-sensitive epitope centered on helix A. Finally, group 1 and 2 HA stem
immunogens could also be given together in a manner analogous to the current
multivalent inactivated influenza vaccines (IIV).
Another approach for inducing an HA stem antibody response involves immu-
nizing sequentially with heterologous chimeric HA immunogens comprising two or
more HAs with the same stem but head regions from different subtypes. This
strategy has elicited heterosubtypic group 1 and group 2 protection in animal
models (50–53). However, the exotic HA heads may still be immunodominant and
potentially interfere with or limit HA stem-specific responses, as it has been shown
in H5 vaccine trials in humans that a transient vaccine-induced boost of the
stem-directed antibody responses can be replaced by immunodominant head-
directed responses over time (49, 54). From a practical clinical perspective, careful
records would need to be maintained to ensure the correct order of administration
of heterologous vaccine products.
Although bacterially produced HA stem-only immunogens from H1, H5, H3, and H7
subtypes have also been reported to protect mice from H3 or H7 influenza virus,
complete protection has only been observed for some homotypic strains (55–57),
indicating that the breadth of response is limited. The immunogens in our study more
closely mimic the native H3N2 and H7N9 HA stems in that they include native N-linked
glycans as well as the membrane-proximal region of the HA stem that are both missing
in the bacterially expressed designs. Eukaryotic expression of HA stem immunogens
may be of particular importance because each native HA stem trimer has nine glycans
and glycans have been observed to guide antibody binding by either masking certain
epitopes (58, 59) or participating as part of an epitope surface (60). Indeed, many
cross-group-reactive HA stem-directed bNAbs are immediately proximal to the HA2
N38 glycan when recognizing group 2 HA (12). Interestingly, the HA stem-directed
bNAbs most frequently elicited from group 1 influenza virus, which does not have N38
glycans, are of the HV1-69 class (48), which is generally incompatible with the N38
glycan, and therefore, they are not cross-group reactive. Thus, group 2 HA stem
immunogens bearing native glycans may provide a selective advantage for eliciting
broad influenza virus antibody responses. However, to date, no experimental data have
shown glycosylated hemagglutinin immunogens to be more effective than nonglyco-
sylated versions. A recently reported particulate vaccine comprising nonglycosylated
HA stem cross-linked to desolvated tandem M2e segments has been shown to elicit
broad cross-group protection in mice (61). However, these particles comprised proteins
derived from multiple host species, strains, and subtypes of influenza virus with the
goal of accumulating breadth, as opposed to the approach used herein of attempting
to achieve breadth through targeting conserved antigenic supersites.
In summary, we have designed group 2 headless HA stem trimers with conforma-
tional and antigenic fidelity to native HA. These antigens were immunogenic in mice
and provided protection against a lethal homosubtypic challenge. Since mice lack
critical genetic elements found in human bNAbs targeting the HA stem, we used a B
cell receptor activation assay to demonstrate the potential for eliciting broadly reactive
human antibody responses. Based on activation of B cells expressing inferred UCA
versions of human antibodies associated with broad cross-neutralizing activity, candi-
date vaccines with antigens displayed on self-assembling ferritin nanoparticles are now
being manufactured for clinical evaluation. Additional animal studies will be performed
in parallel, including testing in mice expressing specific human immunoglobulin genes
and in nonhuman primates. These immunogens represent a step toward achieving the
goal of a vaccine that can elicit protective immunity against drifted seasonal and
pandemic strains of influenza A virus.
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Structure-based design. The crystal structure of A/Finland/486/2004 (H3N2) HA (PDB ID 2YP2) was
used as a template for subtype H3, and the crystal structure of A/Shanghai/2/2013 (H7N9) HA (PDB ID
4LN6) was used as a template for subtype H7. The complete sequences for A/Finland/486/2004 HA and
A/Shanghai/2/2013 (H7N9) HA, including the signal sequence regions not included in the crystal
structures, were obtained from the database records with GISAID accession number EPI397685 and
GenBank accession number YP_009118475.1, respectively. The changes in free energy from point
mutations were estimated using the program DDG_MONOMER (26) from the ROSETTA suite. Loops were
modeled with LOOPY (62), superpositions were performed using UCSF Chimera (63) or LSQMAN (64), and
energy minimization of final models was performed using RELAX (65) from the ROSETTA suite. The
graphics programs PyMOL (66) and UCSF Chimera (63) were used for detailed visual inspection of
structures and the generation of structural figures.
Phylogenetic tree generation for HA sequences. Maximum-likelihood trees were created using the
program MEGA7.0 (67) from 18 representative HA sequences (13) aligned with MUSCLE (68). The stem
regions of HA sequences were defined as residues HA1 10 to 42 and 314 to 329 and HA2 1 to 59 and
93 to 174 (H3 numbering [21]).
Antigenic screening of nanoparticle immunogen designs. Most designs were initially screened in
a high-throughput ELISA format as described previously (23). However, the contributions of individual
mutations within multiple-mutation designs were also assessed by expressing transmembrane versions
of H3 HA stem containing the native C-terminal HA sequence starting with HA2 175 (SVELKSGYKDWIL
WISFAISCFLLCVALLGFIMWACQKGNIRCNICI) on the surface of HEK293F cells and measuring recognition
of bNAbs FI6v3 and CR8020 using flow cytometry. Since HA stem was more readily expressed in this
format, with less stabilization required, this strategy enabled a more sensitive evaluation of HA stem
mutations than the nanoparticle format. Promising designs that exhibited greater FI6v3 and CR8020
binding were subsequently expressed in the nanoparticle format for final evaluation.
Expression and purification of immunogens and antibodies. All H3ssF and H7ssF nanoparticles
and FI6v3, CT149, CR8020, CR6261, MEDI8852, 315-53-1F12, 54-1G07, 04-1D02, and 09-1B12 MAbs were
expressed in 293 Expi cells (Life Technologies) and purified by affinity chromatography (Galanthus nivalis
lectin for the nanoparticles and protein A for MAbs), using previously described methods (13, 17).
Assembly of nanoparticles was assessed by gel filtration with a Superose 6 increase 10/300 GL column
(GE Healthcare). To make MEDI8852 and CR8020 Fabs, IgG was digested with endoproteinase Lys-C (New
England Biolabs) overnight at room temperature (RT). To make CT149 Fab, CT149 IgG containing an
HRV-3C cleavage site engineered in the heavy-chain hinge region was digested using HRV-3C enzyme
overnight at RT. The reactions were assessed by SDS-PAGE and, upon completion, were quenched by the
addition of protease inhibitor cocktail (MilliporeSigma), and Fc and Fab antibodies were separated by
protein A affinity chromatography.
ELISA binding assays. ELISAs were done as previously described (17). Briefly, ELISA plates were
coated with 100 ng/well H1ssF, H3ssF, or H7ssF antigens overnight at 4°C. The plates were then
incubated with IgG or Fab forms of MAbs with dilution series starting at 10 g/ml. For Fab, anti-CH1 MAb
was then bound at 10 g/ml. For testing of mouse sera, H3 HA and H7 HA antigens represented A/Hong
Kong/1/1968 HA and A/Anhui/1/2013, respectively. Mouse serum serial dilutions started at 1:50. Appro-
priate horseradish peroxidase (HRP)-conjugated secondary antibodies were used to detect primary
antibody, followed by a colorimetric detection assay. Linear regression analysis of the absorbance values
(optical density at 450 nm [OD450]) was completed using GraphPad Prism software. Serum endpoint titers
were determined to be the serum dilution that resulted in a 4-fold increase in OD value above the
background level. One-way analysis of variance (ANOVA) with Kruskal-Wallis posttest was used to
compare mean endpoint titers between groups.
Immunoprecipitation assay. Magnetic protein G Dynobeads (Thermo Fisher) were used to capture
FI6v3 MAb according to the manufacturer’s protocol and allowed to incubate for 1 h at RT. FI6v3-bound
Dynobeads were washed 2 times with 1 phosphate-buffered saline (PBS) and incubated with super-
natants from H3ssF or H7ssF expressed in HEK293 cells or purified control protein for 1 h at RT. Beads
were washed 2 times with 1 PBS and heated to 95°C for 10 min to detach bound protein. Proteins were
then analyzed by SDS-PAGE.
Biolayer interferometry binding assays. All biosensors were hydrated in PBS prior to use. CR9114
IgG (10 g/ml diluted in 1% bovine serum albumin [BSA]–PBS) was immobilized on AHC biosensors
through conjugated anti-human Fc antibody (fortéBio). After briefly dipping in assay buffer (1% BSA–
PBS), the biosensors were dipped in various H3ssF and H7ssF constructs (10 g/ml) to capture nano-
particles. The biosensors were then equilibrated in assay buffer for 1 min before being dipped in a 2-fold
dilution series of CR8020, CT149, or MEDI8852 Fab for 5 min, followed by dipping in assay buffer to allow
Fab to dissociate from nanoparticles for 5 min. All assay steps were performed at 30°C with agitation set
at 1,000 rpm in the Octet HTX instrument (fortéBio). Correction to subtract a baseline drift was carried out
by subtracting the measurements recorded for a sensor incubated with no Fab. Data analysis and curve
fitting were carried out using Octet analysis software (version 9.0) as previously described (69, 70).
Experimental data were fitted with the binding equations describing a 1:1 interaction. Global analyses of
the complete data sets assuming binding was reversible (full dissociation) were carried out using
nonlinear least-squares fitting, allowing a single set of binding parameters to be obtained simultaneously
for all concentrations used in each experiment.
Electron microscopy analysis. Samples were diluted to 0.02 mg/ml with buffer containing 10 mM
HEPES, pH 7.0, and 150 mM NaCl and adsorbed to freshly glow-discharged carbon film grids for 15 s. The
grids were washed with the same buffer and stained with 0.7% uranyl formate. Images were collected
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at a nominal magnification of 50,000 semiautomatically using SerialEM (71) on an FEI Tecnai T20
transmission electron microscope operated at 200 kV and equipped with a 2,048- by 2,048-pixel Eagle
charge-coupled-device (CCD) camera. The pixel size was 0.44 nm. Particles were picked automatically
using software developed in-house (Y.T., unpublished data). Particle alignment and reference-free 2-D
classification were performed with SPIDER (72) and Relion 1.4 (73).
DSC. Thermal melting points were determined using a MicroCal VP-capillary differential scanning
calorimeter (DSC; Malvern Instruments). All protein samples were in the range of 0.2 to 0.5 mg/ml and
were extensively dialyzed against PBS. Thermal denaturation was probed at a scan rate of 60°C/h from
30 to 120°C. Buffer correction, normalization, and baseline subtraction procedures were applied before
the data were analyzed using the VP-capillary DSC automated data analysis software.
Mouse immunizations. Animal experiments were carried out in compliance with all pertinent U.S.
National Institutes of Health regulations and policies. The Animal Care and Use Committee of the Vaccine
Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health,
reviewed and approved all animal experiments. Female BALB/cJ mice aged 6 to 8 weeks (Jackson
Laboratory) were immunized (n  10) with 2 g H3ssF or H7ssF and adjuvanted with the Sigma adjuvant
system at 0, 4, and 8 weeks. Mice were inoculated with 100 l intramuscularly, given as 50 l into each
hind leg. Two weeks after the final immunization, sera were collected for measurement of antibody
responses. When appropriate, challenges were performed at 4 to 8 weeks postimmunization. Mice were
inoculated intranasally with a 10 50% lethal dose (LD50) of H3N2 A/Philippines/2/1982 or a 20 LD50
of H7N9 A/Anhui/1/2013. Weight loss was recorded daily for 14 days postchallenge.
Pseudovirus neutralization assays. Lentivirus-based pseudoviruses displaying influenza HA and NA
were produced as previously described (17). Mouse serum was treated with receptor-destroying enzyme
(Denka Seiken). Serial dilutions of mouse sera (4-fold, starting point 1:40, 8 dilutions) were mixed with
either H3N2 A/Wisconsin/67/2005 or H7N9 A/Anhui/1/2013 pseudovirus (whose titers to target 50,000
relative luciferase units [RLU] were previously determined) for 30 min at RT. The virus-pseudovirus
mixture was then added to previously plated 293A cells (ATCC) in triplicate. After 2 h at 37°C and 5% CO2,
fresh Dulbecco modified Eagle medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 2 mM
glutamine, and 1% penicillin–streptomycin was added. Cells were lysed at 72 h, and luciferase substrate
(Promega) was added. Luciferase activity was measured as RLU at 570 nm on a SpectramaxL (Molecular
Devices). Sigmoidal curves, taking averages of triplicates at each dilution, were generated from RLU
readings; 50% neutralization (50% inhibitory concentration [IC50]) titers were calculated considering
uninfected cells as 100% neutralization and cells transduced with only virus as 0% neutralization.
One-way ANOVA with Kruskal-Wallis posttest was used to compare mean IC50 titers between groups.
Determination of inferred UCAs for HA stem antibodies. Paired heavy- and light-chain DNA
sequences for 58 members of the 54-1G07 clonal family (315-54-1G07) were isolated from single IgG B
cells, along with 6 additional heavy-chain DNA sequences from cells for which light chains could not be
amplified (13). A maximum-likelihood phylogenetic tree was constructed from concatenated heavy- and
light-chain sequences and the most recent common ancestor (MRCA) of the lineage was inferred using
DNAML in SONAR (74). This MRCA had 5 residual nucleotide mutations each in the heavy and light chain
(resulting in 2 and 5 amino acid changes, respectively) compared to the sequences of the assigned germ
line VH and VK genes. To construct the final UCA, these changes were reverted to the presumed germ
line sequence. The same procedure was used for 57 paired heavy- and light-chain DNA sequences and
8 unpaired heavy-chain DNA sequences from the 09-1B12 clonal family. This MRCA had 1 residual
nucleotide mutation (1 amino acid change) in the heavy chain and no residual mutations in the light
chain. For the 04-1D02 clonal family, 29 paired heavy- and light-chain DNA sequences and 1 unpaired
heavy-chain DNA sequence were used. The inferred MRCA contained 4 residual nucleotide mutations in
the heavy chain and 6 nucleotide mutations in the light chain (4 and 5 amino acid changes, respectively).
For this clonal family, only changes in VH genes were reverted; the lambda chain of 04-1D02-MRCA was
used with the residual mutations included.
Ninety-three heavy-chain and 83 light-chain sequences were identified for the 16.a.26 clonal family
and 51 heavy-chain and 49 light-chain sequences for the 01.a.44 clonal family from single sorted IgG
B cells. For the heavy chain, a maximum-likelihood phylogenetic tree based upon the V gene sequence
alone was constructed using Geneious (75), with each tree rooted to the respective germ line reference
sequence as listed in the IMGT database. The VDJ junction of clonal members with the lowest mutation
loads was inferred using IMGT V-quest, allowing identification of residues within the V, D, and J gene
segments most likely subject to somatic mutation. To construct the heavy-chain UCA, these changes
were reverted to the presumed germ line sequences. Due to the lack of precision in estimating
N-nucleotide addition, mutations falling at V/D or D/J junctions were not reverted. For the light chains,
an analogous process was used for V and J gene segments.
Generation of B cell lines. B cell lines expressing inferred UCA versions of monoclonal antibodies
were generated by transduction of surface-IgM-negative Ramos cells as previously described (43). Briefly,
DNA encoding VDJ (heavy-chain) and VJ (light-chain) immunoglobulin regions was synthesized by
GenScript and cloned, along with the consensus human IgM C region, into the pLVX-ZsGreen and the
pLVX-mCherry expression vector (both from Clontech), respectively. Each of these vectors was then
cotransfected with the lentivirus packaging plasmid psPAX2 and the vesicular stomatitis virus envelope
protein G (VSV-G)-expressing plasmid pMD2.G (both from Addgene) into HEK293T cells for formation of
lentiviral particles using Lipofectamine 2000 (Thermofisher). Supernatant was harvested 3 days after
transfection and cleared by centrifugation before IgM-negative Ramos cells were cotransduced for both
heavy and light chains. After 5 days, transduced Ramos cells were enriched by cell sorting for the
expression of ZsGreen and mCherry using a FACSAria II interfaced to the FACSDiva software (BD
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Biosciences). This procedure was repeated until a pure double-positive population could be selected. Cell
lines were further enriched for high IgM surface expression by using a fluorescently labeled anti-human
IgM monoclonal antibody.
B cell activation assays. The ability of the different particles to induce calcium flux upon BCR
engagement was measured in vitro using inferred UCA monoclonal antibodies expressed as surface IgM
in Ramos cells as previously described (76). Briefly, 1 million cells (per test) were stained with 0.35 l fura
red (Thermo Fisher Scientific) in 100 l serum-free medium at ambient temperature in the dark for
30 min. After washing, cells were resuspended in 300 l serum-free medium and heated to 37°C for 3 to
5 min in a heated water bath before being acquired on a FACSymphony interfaced to the FACSDiva
software (BD Biosciences). Cells were first acquired for 30 s in the absence of antigen to record baseline
intracellular calcium levels, and then tubes were removed (leaving the acquisition in progress) to add the
antigen and quickly vortexed before being placed back on acquisition for a total time of 180 s.
Nanoparticles were used at the final concentration of 50 nM. An anti-human unlabeled mouse F(ab=)2
anti-IgM (Southern Biotech) was used (1.5 g/test) to determine the maximal induction of calcium flux
measured by the change between the emission of fura red bound to calcium and that of unbound fura
red (ratio) over time. The inferred UCA for 01.a.44 was chosen as a negative control since 01.a.44 is
observed to bind only to group 1 HAs and not to group 2 HAs (not shown). Likewise, the inferred UCAs
for 54-1D07 and 16.a.26 are observed to recognize group 2 HAs only (data not shown).
Accession number(s). The sequences for the inferred UCA versions of the following HA stem
antibodies have been deposited into GenBank under the accession numbers in parentheses: 54-1G07
(MH631450 and MH631451), 04-1D02 (MH997406 and MH997407), 09-1B12 (MH997404 and MH997405),
01.a.44 (MK291363 and MK291365), and 16.a.26 (MK291364 and MK291366).
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